246 related articles for article (PubMed ID: 22527248)
1. Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine.
Chen HM; Wang PH; Chen SS; Wen CC; Chen YH; Yang WC; Yang NS
Cancer Immunol Immunother; 2012 Nov; 61(11):1989-2002. PubMed ID: 22527248
[TBL] [Abstract][Full Text] [Related]
2. Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components.
Lin TJ; Lin HT; Chang WT; Mitapalli S P; Hsiao PW; Yin SY; Yang NS
Mol Cancer; 2015 Sep; 14():174. PubMed ID: 26403780
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin Promotes Mouse 4T1 Tumor Metastasis that Can Be Reversed by a Dendritic Cell-Based Vaccine.
Lin TJ; Liang WM; Hsiao PW; M S P; Wei WC; Lin HT; Yin SY; Yang NS
PLoS One; 2015; 10(10):e0138335. PubMed ID: 26426423
[TBL] [Abstract][Full Text] [Related]
4. Shikonin enhances efficacy of a gene-based cancer vaccine via induction of RANTES.
Chen HM; Wang PH; Aravindaram K; Chen YH; Yu HH; Yang WC; Yang NS
J Biomed Sci; 2012 Apr; 19(1):42. PubMed ID: 22494696
[TBL] [Abstract][Full Text] [Related]
5. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
6. Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines.
Wen CC; Chen HM; Chen SS; Huang LT; Chang WT; Wei WC; Chou LC; Arulselvan P; Wu JB; Kuo SC; Yang NS
J Biomed Sci; 2011 Jun; 18(1):44. PubMed ID: 21689407
[TBL] [Abstract][Full Text] [Related]
7. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
8. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy.
Hatfield P; Merrick AE; West E; O'Donnell D; Selby P; Vile R; Melcher AA
J Immunother; 2008 Sep; 31(7):620-32. PubMed ID: 18600182
[TBL] [Abstract][Full Text] [Related]
9. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
10. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of mammary tumor cells can be induced by shikonin via direct binding-interference with hnRNPA1.
Yin SY; Efferth T; Jian FY; Chen YH; Liu CI; Wang AH; Chen YR; Hsiao PW; Yang NS
Oncotarget; 2016 Jul; 7(28):43629-43653. PubMed ID: 27248319
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.
Wu YG; Wu GZ; Wang L; Zhang YY; Li Z; Li DC
Med Oncol; 2010 Sep; 27(3):736-42. PubMed ID: 19669608
[TBL] [Abstract][Full Text] [Related]
15.
Su H; Zhang Z; Liu Z; Peng B; Kong C; Wang H; Zhang Z; Xu Y
J Biol Chem; 2018 Jun; 293(26):10287-10302. PubMed ID: 29739853
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with CD133(+) melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor.
Miyabayashi T; Kagamu H; Koshio J; Ichikawa K; Baba J; Watanabe S; Tanaka H; Tanaka J; Yoshizawa H; Nakata K; Narita I
Cancer Immunol Immunother; 2011 Nov; 60(11):1597-608. PubMed ID: 21691723
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
18. Necroptosis promotes autophagy-dependent upregulation of DAMP and results in immunosurveillance.
Lin SY; Hsieh SY; Fan YT; Wei WC; Hsiao PW; Tsai DH; Wu TS; Yang NS
Autophagy; 2018; 14(5):778-795. PubMed ID: 29171784
[TBL] [Abstract][Full Text] [Related]
19. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
20. Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns.
Jiraviriyakul A; Songjang W; Kaewthet P; Tanawatkitichai P; Bayan P; Pongcharoen S
World J Gastroenterol; 2019 Aug; 25(29):3941-3955. PubMed ID: 31413529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
